UA127588C2 - Способи застосування та композиції, які містять дулаглутид - Google Patents

Способи застосування та композиції, які містять дулаглутид Download PDF

Info

Publication number
UA127588C2
UA127588C2 UAA202002355A UAA202002355A UA127588C2 UA 127588 C2 UA127588 C2 UA 127588C2 UA A202002355 A UAA202002355 A UA A202002355A UA A202002355 A UAA202002355 A UA A202002355A UA 127588 C2 UA127588 C2 UA 127588C2
Authority
UA
Ukraine
Prior art keywords
dulaglutide
dose
subject
weeks
once
Prior art date
Application number
UAA202002355A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дейвід Ендрю Кокс
Дэйвид Эндрю Кокс
Звонко Мілішевіч
Звонко Милишевич
Лай Сань Зем
Ендрю Гордон Уернер
Эндрю Гордон Уэрнер
Дейвід Бредлі Вудворд
Дэйвид Брэдли Вудворд
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA127588(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA127588C2 publication Critical patent/UA127588C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
UAA202002355A 2017-11-21 2018-11-13 Способи застосування та композиції, які містять дулаглутид UA127588C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Publications (1)

Publication Number Publication Date
UA127588C2 true UA127588C2 (uk) 2023-10-25

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202002355A UA127588C2 (uk) 2017-11-21 2018-11-13 Способи застосування та композиції, які містять дулаглутид

Country Status (21)

Country Link
US (2) US11576950B2 (cg-RX-API-DMAC7.html)
EP (1) EP3713593A2 (cg-RX-API-DMAC7.html)
JP (3) JP7221956B2 (cg-RX-API-DMAC7.html)
KR (2) KR102589234B1 (cg-RX-API-DMAC7.html)
CN (2) CN111356472A (cg-RX-API-DMAC7.html)
AU (2) AU2018372709B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020007817A2 (cg-RX-API-DMAC7.html)
CL (1) CL2020001252A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200202A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000104A (cg-RX-API-DMAC7.html)
EA (1) EA202090971A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20026436A (cg-RX-API-DMAC7.html)
IL (1) IL274563B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200126B1 (cg-RX-API-DMAC7.html)
MA (1) MA50798A (cg-RX-API-DMAC7.html)
MX (1) MX2020005231A (cg-RX-API-DMAC7.html)
PE (1) PE20200847A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550795A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003687RA (cg-RX-API-DMAC7.html)
UA (1) UA127588C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019103875A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613629A (zh) * 2019-03-15 2021-11-05 伊莱利利公司 防腐的制剂
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
JP2023525898A (ja) * 2020-05-19 2023-06-19 エフ. ホフマン-ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
AU2022298662B2 (en) 2021-06-23 2025-06-05 Eli Lilly And Company An incretin analog for use in glycemic control and weight management

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
JP2008525452A (ja) 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Glp−1類似体融合蛋白質製剤
KR20100020516A (ko) * 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Glp-1-fc 융합 단백질 제제
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US20200171129A1 (en) 2017-06-01 2020-06-04 Eli Lilly And Company Therapeutic uses of dulaglutide

Also Published As

Publication number Publication date
JP7221956B2 (ja) 2023-02-14
DOP2020000104A (es) 2020-08-31
BR112020007817A2 (pt) 2020-10-06
WO2019103875A3 (en) 2019-07-25
MA50798A (fr) 2020-09-30
KR102589234B1 (ko) 2023-10-16
EP3713593A2 (en) 2020-09-30
CN111356472A (zh) 2020-06-30
AU2018372709A1 (en) 2020-05-14
SG11202003687RA (en) 2020-06-29
US11576950B2 (en) 2023-02-14
KR20200076705A (ko) 2020-06-29
JP2024056908A (ja) 2024-04-23
WO2019103875A2 (en) 2019-05-31
PE20200847A1 (es) 2020-08-18
MX2020005231A (es) 2020-08-24
US20240189394A1 (en) 2024-06-13
ECSP20026436A (es) 2020-06-30
PH12020550795A1 (en) 2021-04-19
JOP20200126A1 (ar) 2020-05-21
JOP20200126B1 (ar) 2024-04-18
AU2022203372A1 (en) 2022-06-09
CL2020001252A1 (es) 2020-10-30
JP7818412B2 (ja) 2026-02-20
AU2022203372B2 (en) 2025-04-10
IL274563A (en) 2020-06-30
AU2018372709B2 (en) 2022-04-28
US20200330558A1 (en) 2020-10-22
JP2022062153A (ja) 2022-04-19
CR20200202A (es) 2020-08-20
CN120478602A (zh) 2025-08-15
CA3082625A1 (en) 2019-05-31
EA202090971A1 (ru) 2020-08-07
IL274563B2 (en) 2023-12-01
KR20220146656A (ko) 2022-11-01
NZ763815A (en) 2023-11-24
JP2021502379A (ja) 2021-01-28
IL274563B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
JP7818412B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
US12220392B2 (en) Combination composition
JP2021535161A5 (cg-RX-API-DMAC7.html)
CN107496907A (zh) 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品
JP2019501886A5 (cg-RX-API-DMAC7.html)
US20110218206A1 (en) Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
CA3204344A1 (en) Treatment of hemophilia with fitusiran
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
JP2026500140A (ja) 血漿カリクレイン関連障害を処置するための抗血漿カリクレイン抗体投薬レジメン
KR102870956B1 (ko) 조현병의 치료를 위한 일로페리돈
RU2015117995A (ru) Композиции и способы лечения эктодермальной дисплазии
TW202525306A (zh) 用非妥西蘭(fitusiran)治療a型血友病
CA3082625C (en) Methods of using and compositions containing dulaglutide
CN109562149A (zh) C1酯酶抑制剂的药物制剂
EA041605B1 (ru) Способы применения и композиции, содержащие дулаглутид
WO2021255438A1 (en) Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome
Gras Berotralstat. Plasma kallikrein (KLKB1) inhibitor, Treatment of hereditary angioedema attacks
Audhya et al. Agreement between improvements in patient global impression of change and other measures of improvement and attack resolution observed in a phase 2 trial with sebetralstat (KVD900) in patients with hereditary angioedema
CA3035327C (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
Baker New Dosage Forms and Indications Approved by the FDANew Drug/Biologics License Applications Filed by ManufacturerSignificant Labeling Changes or “Dear Health Professional” Letters Related to Safety: New Drugs Approved by the FDA
HK1248551B (en) Iloperidone for the treatment of schizophrenia